pertuzumab + paclitaxel + carboplatin

**Pertuzumab + paclitaxel + carboplatin** is a multi-agent combination chemotherapy and targeted therapy regimen primarily used in the neoadjuvant (pre-surgical) treatment of HER2-positive breast cancer. Pertuzumab is a monoclonal antibody that targets the HER2 receptor, inhibiting its dimerization and downstream signaling. Paclitaxel is a microtubule-stabilizing chemotherapeutic agent that disrupts mitosis, and carboplatin is a DNA-damaging alkylating-like platinum compound. This regimen is anthracycline-free and aims to maximize tumor response while reducing certain toxicities. The combination has demonstrated high pathologic complete response rates and is considered an alternative to other HER2-directed regimens. The use of pertuzumab and paclitaxel is largely in the realm of HER2-positive breast cancer, with ongoing clinical studies evaluating efficacy and safety[2].